{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-239422","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.605462+00:00","generated_at":"2026-06-23T14:17:55.939721+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones","bullets":["Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.","Potential milestone payments: $10M for proof-of-concept/clinical milestones, $50M for regulatory/commercial milestones.","Transaction requires stockholder approval; Board unanimously approved; termination fee of $1.5M.","Retention agreements amended for CEO Rahul Ballal and CFO/COO Michael Gray, with 50% payable on definitive agreement and 50% on closing.","Company will continue evaluating strategic alternatives post-sale, including possible liquidation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-239422","json":"https://secwatch.observer/filing/0001193125-22-239422.json","markdown":"https://secwatch.observer/filing/0001193125-22-239422.md","text":"https://secwatch.observer/filing/0001193125-22-239422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/0001193125-22-239422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/d396958d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:17:55.939721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}